Medigene AG will present at ASGCT to be held October 16-17, 2024 in Philadelphia, PA and will host a R&D event on October 10, 2024 at 4.30 p.m. CEST / 10:30 a.m. ET. 📃 The poster to be displayed will showcase the Company’s newly introduced technology, UniTope & TraCR, an innovative combination of universal TCR tagging and tracking. Reade here the full PR: https://lnkd.in/dt8Sq4EW More information on the conference: https://lnkd.in/eswMGcxg If you want to learn more about our optimal 3S TCRs and their utilization across a wide range of modalities, including TCR-engineered T cell therapies, TCR-guided T cell engager therapies, and TCR-natural killer cell therapies, join our R&D event. 📅 Thursday, October 10, 2024 ⌚ 4.30 p.m. CEST / 10:30 a.m. ET. 👉 Follow this link to register: https://lnkd.in/eX7RM7J7
Info
Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
- Website
-
http://www.medigene.com
Externer Link zu Medigene AG
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1994
- Spezialgebiete
- Immunotherapies und T Cell receptors TCR
Orte
-
Primär
-
-
Lochhamer Strasse 11
Planegg, BY 82152, DE
Beschäftigte von Medigene AG
-
Pamela Keck
-
Tristan Holland
Team Leader - Senior Scientist at Medigene AG | Medigene Immunotherapies GmbH | Pre-Clinical Development of Cellular Immunotherapies (TCR-Ts)
-
Julia Heilmann-Brohl
Senior Scientist bei MediGene AG
-
Dolores J. Schendel
Chief Scientific Officer at Medigene AG
Updates
-
📣 Our Head of Head of Clinical Strategy and Development Kirsty Crame - van Nierop recently had the opportunity to connect with the Healthcare Team from the Edison Group discussing our broad and active pipeline focused on a range of modalities including TCR-engineered T cell therapies and TCR-guided T cell engager therapies. Kirsty highlighted our lead candidate MDG1015, a first-in-class, 3rd generation TCR-T therapy targeting NY-ESO-1/LAGE-1a armored and enhanced by our with our PD1-41BB costimulatory switch protein. MDG1015 has recently received clearance from the US FDA for our investigational new drug (IND) application, paving the way for its use in multiple solid tumor indications. The interview covered also our ongoing partnerships with #BioNTech, #Regeneron and #WuXiBiologics. 👉 Watch here the full interview: https://lnkd.in/gapQkYpr #platform2patient #TCR #TCRT #CancerTherapies #ImmunoOncology #CellTherapy
Medigene AG (FSE: MDG1) is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (#TCR)-guided therapies with the aim of effectively eliminating #cancer. #Medigene has a broad and active pipeline focused on a range of modalities. Notably, lead programme #MDG1015 is a first-in-class, third-generation T cell receptor-engineered T cell (TCR-T) #therapy, for which, the company recently received US #FDA clearance for its investigational new drug application for multiple solid #tumour indications. MDG1015 is expected to enter the clinic by end-2024, subject to additional #financing. Edison’s Healthcare Team recently caught up with Kirsty Crame - van Nierop, Head of Clinical Strategy and Development of #MDG1. Watch the full interview here: https://lnkd.in/gapQkYpr
-
🔊 Medigene Virtual R&D Event is Coming Soon! We are thrilled to discuss our specific, sensitive, and safe T cell receptor (3S TCR) technology in shaping the future for cancer treatment. 📅 Thursday, October 10, 4.30pm CET / 10.30am ET 🔗 Register here: https://lnkd.in/eX7RM7J7
Join Medigene AG’s upcoming webinar, Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies. 🎥🔬 This R&D event will focus on its optimal 3S (specific, sensitive and safe) T cell receptors for T cell receptor-guided precision #immunotherapies, including its lead programme MDG1015. 📅 Thursday, 10 October 🕞 10:30 AM ET / 4:30 PM CET / 3:30 PM BST Register now: https://lnkd.in/eX7RM7J7 #TCR #TCRT #CancerTherapies #ImmunoOncology #CellTherapy
Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies
edisongroup.com
-
👩🔬 Barbara Lösch PhD, our Head of Technology and Innovation, joined the DACH Symposium 2024: Empowering Research & Drug Development in Biomedicine, taking place in Basel on September 24, 2024. She provided an overview of our Universal tagging and tracking system UniTope & TraCR technology. This technology is a component of our End-to-End Platform, featuring two specialized tools that uniquely tag TCRs and accurately track their location. This enables precise monitoring of TCR-guided cell therapies, including their proliferation, persistence, and localization, both in vitro and in vivo. As a result, it provides essential insights into the efficacy and underlying mechanisms of cell therapies. 👉Recent data on UniTope & TraCR technology were presented at the ESMO Congress 2024 in Barcelona. Find here the poster: https://lnkd.in/d5xb6Nx6 👉More information about the conference: https://lnkd.in/g8nJE3ix
-
👉Medigene AG strengthens protection of its KRAS library with filing a new patent application for MDG2021. Read here the PR: https://lnkd.in/dHGqCZWC 🧬🧫🧪 MDG2021 marks the second candidate within the KRAS library targeting KRAS G12D (HLA-A*11) for which the Company announced lead selection in June 2024. Full PR on lead selection: https://lnkd.in/dhzm-tDj Latest data on MDG2021 have been presented at the ESMO Congress 2024 in Barcelona. Find here the poster: https://lnkd.in/dTUXpSHM #platform2patient #TCR #TCRT #CancerTherapies #ImmunoOncology #CellTherapy
-
🌏 World Cancer Research Day is marked every year on September 24, focusing on ongoing efforts to advance cancer research globally. The day emphasizes the importance of collaboration between institutions, governments, and industries to accelerate scientific discoveries and improve outcomes for those affected by cancer. 🎗🧬🧫🧪👩🔬 At Medigene AG, our goal is to fully leverage our End-to-End Platform to design and develop TCR-guided therapies across a range of drug modalities and therapeutic indications. By harnessing this platform, we aim to create next generation TCRs for precision immunotherapies that can address multiple forms of cancer, delivering effective treatment solutions to patients. #WorldCancerResearchDay #CancerResearch #platform2patient #TCR #TCRT #CancerTherapies #ImmunoOncology #CellTherapy
-
📣 Baader Investment Conference is calling Our CEO, Selwyn Ho and Pamela Keck, VP Investor Relations and Corporate Communications, will join the Baader Investment Conference on September 25. They are looking forward to discuss Medigene AG's latest business developments and dive into the groundbreaking advancements of our highly specific, sensitive, and safe TCRs, designed for use in TCR-guided precision immunotherapies. Last year, more than 700 investors from 30 different countries participated in the Baader Investment Conference. The event featured approximately 3,000 individual and group presentations, offering investors the opportunity to engage in in-depth discussions with representatives from 230 companies. More information on the conference: https://lnkd.in/dybEaPm #baaderbank #capitalmarkets #investorrelations #Medigene #platform2patient #tcr #TCR #TCRT #CancerTherapies #ImmunoOncology #CellTherapy
-
In a recent interview with Kapitalerhöhungen.de, our CEO, Selwyn Ho, shared Medigene’s exciting advancements in TCR-T therapies. He discussed the immense potential of our third generation TCR-T therapies, such as MDG1015, designed to offer more effective, safer, and durable treatment options for patients with solid tumors. He explored the possibilities of TCRs for multiple, precision immunotherapy modalities including TCR-T therapies, TCR-guided T cell engager therapies, and TCR-natural killer cell therapies. Selwyn highlighted the significance of the FDA's clearence for MDG1015 and shared updates on our strategic collaborations with BioNTech, Regeneron, and WuXi Biologics. Read the full interview (in German) here: https://lnkd.in/dKV8yzdY #TCR #TCRT #CancerTherapies #ImmunoOncology #CellTherapy
Medigene CEO Dr. Selwyn Ho: „Ein entscheidender Erfolg, auf unserem Weg, diese vielversprechende Therapie Patienten mit soliden Tumoren anbieten zu können“
kapitalerhoehungen.de
-
👉 Join us for Medigene's Virtual R&D Event! We’re excited to announce that Medigene AG will be hosting a virtual R&D event on Thursday, October 10, 2024, at 4:30 pm CET / 10:30 am ET. Learn how our specific, sensitive, and safe T cell receptor (3S TCR) technology is shaping the future of cancer treatment. What's on the agenda? Medigene’s management will provide an in-depth discussion on their 3S TCR technology, focusing on its applications in TCR-T therapies, TCR-guided T cell engager therapies, and TCR-NK therapies. Principal Investigator of the EPITOME1015-I trial, Dr. David B. Zhen, Associate Professor at the Fred Hutchinson Cancer Center and the University of Washington, will deliver a comprehensive overview of MDG1015, Medigene AG leading third generation TCR-T therapy program. The final part will cover an overview of Medigene’s proprietary End-to-End Platform and its modular approach to advancing TCR-guided therapies. 💬 A live Q&A session will follow the presentations, providing an opportunity to engage with our management team. Don’t miss the chance to learn about the future of TCR-guided precision immunotherapies and how Medigene is pushing the boundaries of innovation! 🔗 Register here: https://lnkd.in/dsWx9vWw
-
🙎♀️ September is dedicated to raising awareness about gynecological cancers including ovarian cancer. This month focuses on increasing understanding, promoting early detection and supporting patients. 👨🔬 👩🔬 At Medigene AG, we are generating optimal 3S (sensitive, specific and safe) TCRs with unique and distinctive attributes that can be utilized in multiple therapeutic modalities, including TCR-T therapies, TCR-guided T cell engager therapies and TCR-natural killer cell therapies. Our lead program, MDG1015, a third generation TCR-T therapy designed to target the cancer-testis antigen NY-ESO-1/LAGE-1a recently received FDA clearance for an Investigational New Drug (IND) application. Read here the PR : https://lnkd.in/emfCZDqw More information on MDG1015 here: https://lnkd.in/d6k_fakE #GynecologicCancerAwarenessMonth, #GCAM, #MoveTheMessage #Move4Her. #platform2patient
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang6.286.413,00 $